Electronic Decision Aid for Adenocarcinoma
Study Summary
This trial will compare how effective an electronic decision aid tool is versus a traditional genetic counselor session for people with ovarian or pancreatic cancer. The decision aid is used to treat adenocarcinoma, and there is no placebo group in this trial. The aid has previously been approved by the FDA for a different condition.
Eligible Conditions
- Adenocarcinoma
- Ovarian Epithelial Carcinoma
Treatment Effectiveness
Effectiveness Progress
Other trials for Adenocarcinoma
Study Objectives
3 Primary · 4 Secondary · Reporting Duration: Initial recorded recommendation/referral for genetic testing until the date of sample collection, assessed up to 6 months
Trial Safety
Safety Progress
Other trials for Adenocarcinoma
Trial Design
2 Treatment Groups
Genetic counselor Arm
1 of 2
Electronic decision aid arm
1 of 2
350 Total Participants · 2 Treatment Groups
Primary Treatment: Electronic Decision Aid · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.